Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

Johnson, Bankole A.; Ait-Daoud, Nassima; Bowden, Charles L.; DiClemente, Carlo C.; Roache, John D.; Lawson, Kevin; Javors, Martin A.; Jennie, Z.

doi:10.1016/s0140-6736(03)13370-3

Cited by 673 publications

(531 citation statements)

References 18 publications

Supporting

Mentioning

469

Contrasting

Unclassified

Order By: Relevance

“…The high topiramate dose was chosen to correspond with the apparent minimal effective daily dose that was observed in the clinical trial for alcohol dependence (Johnson et al, 2003). Notably, however, this was an estimate because in that study, topiramate dose was confounded by the effect of time, as a paradigm of escalating dose over an 8-week period was employed.…”

Section: Choice Of Medication Dose and Its Preparationmentioning

confidence: 99%

“…Topiramate, a sulfamate-substituted fructopyranose derivative, has been shown to be efficacious in the treatment of both alcohol (Johnson et al, 2003) and cocaine (Kampman et al, 2004) dependence, and to promote smoking cessation among alcohol-dependent individuals who smoke (Johnson et al, 2005a). These therapeutic effects have been attributed to its hypothesized potential to reduce levels of cortico-mesolimbic dopamine, the primary neurochemical substrate for the acquisition and maintenance of drug-seeking behavior for the majority of abused drugs including alcohol, cocaine, tobacco, and amphetamines (Hemby et al, 1997;Wise, 1998).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Johnson

Roache

Ait-Daoud

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

Methamphetamine-dependent individuals often cite the need to maintain enhanced cognitive performance and attention as a reason for continuing or relapsing to drug-taking. Further, methamphetamine addicts might not comply with taking a potentially therapeutic medication if it had a profound effect on these cognitive processes. Topiramate, a sulfamate-substituted fructopyranose derivative, has been suggested as a putative therapeutic medication for treating methamphetamine dependence. Examination of topiramate's effects on cognitive performance and attention is a clinically and scientifically important component of understanding its potential therapeutic profile. In 10 male and female individuals who met DSM-IV criteria for methamphetamine dependence, we examined the effects of low (50 mg b.i.d.)-and high (100 mg b.i.d.)-dose topiramate -in both the presence and absence of low (15 mg)-and high (30 mg)-dose intravenous methamphetamine -on cognitive performance, attention, and concentration on the rapid visual information processing task and the digit symbol substitution test. Intravenous methamphetamine enhanced cognitive performance, attention, and concentration among recently withdrawn methamphetamine addicts -an effect that hitherto had not been well characterized. Topiramate's cognitive effects were mixed and rather paradoxical, with a tendency to improve attention and concentration both alone and in the presence of methamphetamine while worsening psychomotor retardation. No deleterious interaction occurred between topiramate and methamphetamine on any of these cognitive processes. While clinical studies with topiramate should Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access

show abstract

Section: Choice Of Medication Dose and Its Preparationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Johnson

Roache

Ait-Daoud

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…We do, however, consider this to be unlikely because the maximum dose of topiramate that we used (i.e., 200 mg/day) does appear sufficient to antagonize the central dopamine-mediated reinforcing effects of drugs of abuse such as alcohol (Johnson et al, 2003) and cocaine (Johnson, 2005;Kampman et al, 2004) in clinical settings and is, therefore, a pharmacologically relevant dose.…”

Section: Discussionmentioning

confidence: 99%

“…The maximum topiramate dose was chosen to represent the putative minimal effect dose observed in clinical trials for alcohol dependence (Johnson et al, 2003) and cocaine dependence (Ait-Daoud and Johnson, 2004;Kampman et al, 2004). The lower topiramate dose was half of the maximum dose.…”

Section: Choice Of Medication Dose and Its Preparationmentioning

confidence: 99%

Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals

Johnson

Wells

Roache

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

Previously, we have shown that orally administered topiramate, a sulfamate-substituted fructopyranose derivative, appears to accentuate rather than diminish some aspects of methamphetamine-induced positive subjective mood and cognitive performance. One possible mechanism by which this might occur would be for topiramate to increase plasma methamphetamine level. Such an effect also would be expected to enhance methamphetamine-induced hemodynamic response. We, therefore, studied -in the same experiment from which the previous findings originated -the effects of topiramate on the kinetic profile and hemodynamic response to methamphetamine. In a 27-day inpatient study, 10 methamphetamine-dependent individuals participated in a double-blind, placebo-controlled, cross-over design, with oral doses of topiramate (0, 100, and 200 mg) administered as a pretreatment before intravenous doses of methamphetamine (0, 15, and 30 mg). The 3 × 3 factorial combination of topiramate and methamphetamine resulted in a sequence of the nine treatments administered to each subject in an order determined by a 9 × 9 Latin Square design. Methamphetamine alone was associated with prototypical increases in hemodynamic response that were not altered in the presence of topiramate. While there was no significant kinetic interaction between topiramate and methamphetamine, there was a non-significant trend for topiramate to increase plasma methamphetamine level. No significant adverse events were reported. The combination of topiramate and methamphetamine at pharmacologically relevant doses appears to be safe. Larger laboratory studies with chronic dosing regimens are needed to establish whether or not there is a kinetic interaction between topiramate and methamphetamine.

show abstract

“…The GABA B receptor agonist baclofen dependently reduced the nicotine-, morphine-, and cocaine-evoked DA release in the shell of the NAc and also had been proposed as a potential therapeutic agent for the clinical treatment of several forms of drug addiction (Fadda et al, 2003). These drugs have shown promising results in animal studies (Dewey et al, 1998;Di Ciano and Everitt, 2003) and in preliminary clinical trials in cocaine-addicted subjects (Brodie et al, 2003;Gonzalez et al, 2003) and alcoholics (Johnson et al, 2003).…”

Section: Da and Heroin Addiction Treatment Implicationsmentioning

confidence: 99%

Positron Emission Tomography Molecular Imaging of Dopaminergic System in Drug Addiction

Hou¹,

Tian²,

Zhang³

2012

The Anatomical Record

View full text Add to dashboard Cite

Dopamine (DA) is involved in drug reinforcement, but its role in drug addiction remains unclear. Positron emission tomography (PET) is the first technology used for the direct measurement of components of the dopaminergic system in the living human brain. In this article, we reviewed the major findings of PET imaging studies on the involvement of DA in drug addiction, especially in heroin addiction. Furthermore, we summarized PET radiotracers that have been used to study the role of DA in drug addiction. To investigate presynaptic function in drug addiction, PET tracers have been developed to measure DA synthesis and transport. For the investigation of postsynaptic function, several radioligands targeting dopamine one (D1) receptor and dopamine two (D2) receptor are extensively used in PET imaging studies. Moreover, we also summarized the PET imaging findings of heroin addiction studies, including heroin-induced DA increases and the reinforcement, role of DA in the long-term effects of heroin abuse, DA and vulnerability to heroin abuse and the treatment implications. PET imaging studies have corroborated the role of DA in drug addiction and increase our understanding the mechanism of drug addiction. Anat Rec, 295:722-733, 2012. V C 2012 Wiley Periodicals, Inc.Key words: positron emission tomography; dopamine; dopamine receptor; drug addiction; heroin BRAIN DOPAMINERGIC SYSTEM Dopamine (DA) is a catecholamine neurotransmitter in the nervous system that permits individual nerve fibers (neurons) to communicate with each other. DA has many functions in the brain, including important roles in behavior and cognition, voluntary movement, motivation, punishment and reward, sleep, mood, attention, working memory, and learning (Smythies, 2005).

show abstract

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

Cited by 673 publications

References 18 publications

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals

Positron Emission Tomography Molecular Imaging of Dopaminergic System in Drug Addiction

Contact Info

Product

Resources

About